Department of Pharmacology, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Autophagy. 2010 Nov;6(8):1057-65. doi: 10.4161/auto.6.8.13365.
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death worldwide. Drug treatments for HCC have been largely unsuccessful. Histone deacetylase inhibitors can reactivate tumor suppressor genes in cancer cells and serve as potential anti-cancer drugs. Two potent HDAC inhibitors OSU-HDAC42 and SAHA induced autophagy in HCC cells as revealed by transmission electron microscopy, immunofluorescence and LC3-II accumulation. We found that SAHA and OSU-HDAC42 induced autophagy through downregulation of Akt/mTOR signaling and induction of ER stress response. Inhibition of autophagy by 3-MA or Atg5 knockout reduced SAHA-induced cytotoxicity, indicating that SAHA-induced autophagy led to cell death. Our results show that the combination of autophagy inducers with SAHA might be attractive for the treatment of HCC and pharmacological targeting of autophagy provides promise for the management of cancer therapy.
肝细胞癌(HCC)是全球第五大常见癌症和第三大癌症死亡原因。HCC 的药物治疗大多不成功。组蛋白去乙酰化酶抑制剂可以在癌细胞中重新激活肿瘤抑制基因,并作为潜在的抗癌药物。透射电子显微镜、免疫荧光和 LC3-II 积累显示,两种有效的 HDAC 抑制剂 OSU-HDAC42 和 SAHA 诱导 HCC 细胞自噬。我们发现,SAHA 和 OSU-HDAC42 通过下调 Akt/mTOR 信号和诱导 ER 应激反应诱导自噬。自噬抑制剂 3-MA 或 Atg5 敲除减少了 SAHA 诱导的细胞毒性,表明 SAHA 诱导的自噬导致细胞死亡。我们的结果表明,自噬诱导剂与 SAHA 的联合应用可能对 HCC 的治疗具有吸引力,并且自噬的药理学靶向为癌症治疗的管理提供了希望。